Eczema drug study pulled before it started
NCT ID NCT04761978
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to see how well JAK inhibitors work for adults with moderate-to-severe eczema in real-world settings. It planned to track skin improvement, itching, sleep, and side effects. However, the study was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- JAK inhibitors
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Started
-
Sep 2021
- Finished
-
Sep 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients assessed by French members of the Groupe de Recherche sur l'Eczema Atopique.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults * moderate to severe atopic dermatitis * treated by JAK inhibitors between december 2020 and september 2021 * inefficiency, loss of efficiency or contra-indication of previous systemic agent, DUPILUMAB or phototherapy * ineligibility to French ongoing clinical trials Exclusion Criteria: * Children * mild atopic dermatitis * eligibility to CICLOSPORINE, METHOTREXATE, DUPILUMAB, phototherapy * eligibility to French ongoing clinical trials * patients' opposition for the use of their records * follow up \<3 months
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Dermatitis, atopic are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hop Claude Huriez Chu Lille
Lisle-sur-Tarn, 59037, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new antibody calm stubborn eczema when steroids fall short?
- Can a switch to goat milk formula prevent baby eczema?
- Can a new injection calm severe eczema in kids?
- Real-World dupixent: does it live up to the hype for eczema?
- Scientists hunt for biological clues to severe childhood eczema
- Can a drug calm severe eczema itch when the rash is mild? a new study investigates